Trial
NCT02603146
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Autoimmunity Centers of Excellence
Condition
Healthy Participants
Intervention
Hydroxychloroquine
Why stopped
Enrollment was closed before reaching the target. In the 1st interim analysis after enrollment closure, the follow up \& treatment of active participants were stopped early due to evidence of futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-12